Philip Rosenthal, MD

Phone: 415-476-5892
UCSF Box: 0136
UCSF Profile

Project Sponsor Location(s) Topics Start End
A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination with Peginterferon alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17 Infected With Genotype 1 Hepatitis C Virus Vertex Pharmaceuticals, Inc. United States Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment, Pediatrics
A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection Gilead Sciences, Inc. United States Infectious Disease
Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with Genotype 2 or 3 Chronic HCV Infection Gilead Sciences, Inc. United States Infectious Disease, Pharmacology and Drug Treatment
Childhood Liver Disease Research and Education Network (ChiLDREN) - UCSF (CC) NIH National Institute of Diabetes and Digestive and Kidney Diseases United States Pediatrics
A 48-52 Month Blinded-Outcomes Follow up Study of Patients Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-205 Quintiles, Inc United States
GS-US-334-1113: A Phase 4, a Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Diret Acting Antiviral (DAA) in Gilead- Sponsored Chronic Hepatitis C Infection Trial Gilead Sciences, Inc. United States Drug and Diagnostics Development